Loading
PF-08046054 is an experimental antibody-drug conjugate from Pfizer in phase 3 trials for non-small-cell lung cancer, aimed at PD-L1.
PF-08046054 is an antibody-drug conjugate developed by Pfizer. Its target is PD-L1 (the sponsor names PD-L1). ClinicalTrials.gov describes the intervention as: Antibody Drug Conjugate Participants will receive PF-08046054, administered as an IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07144280 (A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)), in non-small-cell lung cancer. The largest, NCT07144280, plans to enrol 680 participants with primary completion expected 2028-03-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate directed at PD-L1, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to PD-L1.
1.PF-08046054's antibody arm binds PD-L1 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PF-08046054" OR ABSTRACT:"PF-08046054" OR TITLE:"SGN-PDL1V" OR ABSTRACT:"SGN-PDL1V") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PF-08046054, not a curated reading list.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), PD-L1 and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.
Shares Pfizer (incl. Seagen), Non-small-cell lung cancer and the tag pipeline.